01—Abstract
Summary
Summary of the 8-K filed June 3, 2024. Cited figures are marked; the original filing is the authoritative source.
On June 3, 2024, Edwards Lifesciences (EW) disclosed that it has entered into a Stock and Asset Purchase Agreement to sell its Critical Care product group to Becton, Dickinson and Company (BD) for $4.2 billiona in cash.
The transaction replaces the previously announced spin-off of Critical Care, which Edwards is no longer pursuing. The sale is structured as an all-cash deal, and Edwards expects the after-tax proceeds to fund strategic growth investments. Management framed the divestiture as a way to sharpen focus on structural heart disease, the company's core strategy.
Proceeds are intended to strengthen balance sheet flexibility for investments in aortic, mitral, tricuspid and pulmonic technologies, as well as interventional heart failure. The company stated that the transaction is expected to have an immaterial impact on 2024 adjusted EPS if it closes as anticipated. The deal is expected to close by the end of 2024, subject to customary conditions, including required antitrust and foreign investment approvals.
Investors should monitor regulatory progress, as failure to close or delays could affect the company's business and share price. Other key terms, such as break fees and the precise after-tax proceeds, were not disclosed in this filing.
02—Key points
Key Highlights
- Edwards will sell its Critical Care product group to BD for $4.2 billion in all-cash consideration.
- The sale replaces the previously announced spin-off of Critical Care, which Edwards is no longer pursuing.
- Proceeds, on an after-tax basis, are earmarked to fund strategic growth investments in structural heart disease.
- Management expects the 2024 impact on adjusted EPS to be immaterial if the deal closes as planned.
- The transaction is expected to close by the end of 2024, pending antitrust and foreign investment approvals.
- The divestiture supports Edwards' focus on aortic, mitral, tricuspid, pulmonic and interventional heart failure technologies.
- Critical Care will continue operating in Irvine, CA, led by current corporate vice president Katie Szyman.
03—Questions
Frequently Asked Questions
Why is Edwards selling Critical Care instead of spinning it off?
Edwards says the sale to BD gives it greater balance sheet flexibility and cash to reinvest in its core structural heart strategy. The company states its underlying rationale for separating Critical Care has not changed, but the cash sale now achieves that goal instead of a spin-off.
How much will Edwards receive from the transaction?
The purchase price is $4.2 billion in cash. Edwards has not disclosed the after-tax proceeds in this filing, though it says it will use them to fund strategic growth investments.
Will this deal materially affect Edwards' earnings?
No. If the transaction closes as expected, Edwards says the impact on 2024 adjusted EPS would be immaterial. The filing does not provide longer-term earnings guidance related to the divestiture.
What could prevent the deal from closing?
Closing depends on satisfying customary conditions, including receipt of required antitrust and foreign investment approvals. The filing also flags risks such as litigation, disruption to management focus, customer relationship effects, and transaction costs.
When is the transaction expected to be completed?
Edwards expects the transaction to close by the end of 2024, subject to the satisfaction or waiver of the closing conditions described in the filing.
04—Continue